GAM
RKDA icon

Gemmer Asset Management’s Arcadia Biosciences RKDA Stock Holding History

Gemmer Asset Management’s Portfolio RKDA Stock Details RKDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-30
Closed -$4K – 1409
2021
Q2 		$4K Hold
30
– – ﹤0.01% 1205
2021
Q1 		$3K Buy
+30
New +$3.68K ﹤0.01% 1288

Other funds holding RKDA

AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MA
MYDA Advisors Woodmere, New York $608M AUM 77.08% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Gemmer Asset Management's RKDA Position: Q3 2021 in Review

Gemmer Asset Management sold out of Arcadia Biosciences (RKDA) in Q3 2021, closing a stake of 30 shares — an estimated $4K sold.

Gemmer Asset Management first reported a position in RKDA in Q1 2021 and held it in 2 quarters. The position peaked at $4K in Q2 2021. 21 funds tracked by Wall St. Rank hold RKDA as of Q3 2021.

  • Gemmer Asset Management reported no remaining Arcadia Biosciences position as of Q3 2021 after selling out during the quarter.
  • Gemmer Asset Management sold 30 Arcadia Biosciences shares in Q3 2021, an estimated $4K.
  • Gemmer Asset Management first reported a position in Arcadia Biosciences in Q1 2021 and held it in 2 quarters.
  • Gemmer Asset Management's Arcadia Biosciences position peaked at $4K in Q2 2021.
  • 21 funds tracked by Wall St. Rank held Arcadia Biosciences as of Q3 2021.

Based on Gemmer Asset Management's 13F filing for Q3 2021, filed 19 Oct 2021.